HC Wainwright Brokers Increase Earnings Estimates for Kamada

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Kamada in a research report issued on Thursday, January 8th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.44 per share for the year, up from their prior forecast of $0.41. HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The business had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Benchmark reissued a “buy” rating on shares of Kamada in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Kamada Price Performance

KMDA opened at $8.06 on Monday. Kamada has a 12 month low of $5.54 and a 12 month high of $9.15. The business has a 50-day moving average of $7.06 and a two-hundred day moving average of $7.13. The stock has a market capitalization of $463.53 million, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 0.68 and a beta of 0.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KMDA. ARK Investment Management LLC bought a new stake in shares of Kamada in the second quarter worth $1,972,000. Goldman Sachs Group Inc. bought a new position in shares of Kamada during the first quarter worth about $497,000. Huntleigh Advisors Inc. grew its stake in Kamada by 3.9% in the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after purchasing an additional 5,151 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Kamada by 3.1% in the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after buying an additional 7,925 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Kamada by 43.6% during the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 12,442 shares in the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.